Document is current
Any future updates will be listed below
-
Authors
Wu, Xiaohua
Mao, Yimin
Xu, Nong
Bai, Yuxian
Wang, Dong
Chen, Xiaojun
Yin, Xianli
Deng, Yanhong
Yang, Jianwei
Zhang, Jieqing
Tang, Jie
Huang, Yi
Li, Jiayi
Luo, Suxia
Zheng, Hong
Zhao, Weidong
Xu, Miaomiao
Li, Nan
Mao, Yixiang
Gozman, Alexander
Xu, Jianming https://orcid.org/0000-0003-4467-6021
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02628067 at ClinicalTrials.govDocuments that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
https://doi.org/10.1136/jitc-2023-007440
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
https://doi.org/10.1136/jitc-2020-000564
Targeted therapy in cervical cancer
https://doi.org/10.1136/esmoopen-2018-000462
Combined modality management of advanced cervical cancer including novel sensitizers
https://doi.org/10.1136/ijgc-2021-003137
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
41 External reproducibility of PD-L1 IHC 22C3 pharmDx for cervical cancer at CPS ≥ 1 and CPS ≥ 10
https://doi.org/10.1136/jitc-2022-sitc2022.0041
KEYNOTE-158: Final analysis of pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors.
https://doi.org/10.1200/jco.2024.42.16_suppl.e15137
Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth
https://doi.org/10.1136/jitc-2020-000785
Combined modality including novel sensitizers in gynecological cancers
https://doi.org/10.1136/ijgc-2021-002529
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Pembrolizumab in Patients of Chinese Descent with Microsatellite Instability-high/Mismatch Repair Deficient Advanced Solid Tumors: KEYNOTE-158 Final Analysis
https://doi.org/10.1007/s12325-025-03142-6
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
https://doi.org/10.1136/jitc-2021-002552
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
https://doi.org/10.1136/jitc-2022-006658
-
Funding
Funding for this research was provided by:
Merck
- License Information
-
More Information
Article History
Received: 27 November 2024
Accepted: 11 February 2025
First Online: 22 March 2025
Declarations
:
: Miaomiao Xu, Nan Li and Yixiang Mao are employees of MSD (China) Co., Ltd. Alexander Gozman is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and stockholders of Merck & Co., Inc., Rahway, NJ, USA. Xiaohua Wu, Yimin Mao, Nong Xu, Yuxian Bai, Dong Wang, Xiaojun Chen, Xianli Yin, Yanhong Deng, Jianwei Yang, Jieqing Zhang, Jie Tang, Yi Huang, Jiayi Li, Suxia Luo, Hong Zheng, Weidong Zhao and Jianming Xu reported that their institutions received research funds from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
: All patients provided written informed consent. The trial was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guidelines, and local regulations. The protocol and all amendments were approved by the appropriate institutional review boards or ethics committee at each participating institution, and these approval numbers can be found as supplementary material.
